Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

780519

registered interest
date	30/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many Yellow Cards submitted to the Medicines and Healthcare Products Regulatory Agency for the HPV vaccination were classified as serious; and how many of those cases were reviewed to establish whether the patient had returned to full health in each of the last 12 months.
tabling member constituency	Mansfield
tabling member printed	Ben Bradley
uin	110360
answer	answer is ministerial correction date of answer 07/11/2017 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) encourages anyone to report a suspected adverse reaction (ADR) to a vaccine or medicine through the Yellow Card Scheme:</p><p> </p><p><a href="http://www.mhra.gov.uk/yellowcard" target="_blank">www.mhra.gov.uk/yellowcard</a></p><p>A Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine or medicine may have been the cause. Such reports are kept under continual review to identify potential new risks.</p><p> </p><p>Between 31 October 2014 – 30 October 2017 a total of 649 serious suspected adverse reaction (ADR) reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme (data run date: 1 November 2017). In this three year period, at least 1 million doses of HPV vaccine were administered in the United Kingdom.</p><p> </p><p>A breakdown of UK serious suspected spontaneous ADR reports received via the Yellow Card Scheme beween 31 October 2014 – 30 October 2016 by brand and year received is shown in the following table.</p><p> </p><table><tbody><tr><td><p>HPV Vaccine</p></td><td><p>Number of serious reports</p></td></tr><tr><td><p>HPV brand unspecified</p></td><td><p>181</p></td></tr><tr><td><p>Cervarix</p></td><td><p>64</p></td></tr><tr><td><p>Gardasil</p></td><td><p>390</p></td></tr><tr><td><p>Gardasil 9</p></td><td><p>18</p></td></tr><tr><td><p>Total</p></td><td><p>649</p></td></tr></tbody></table><p> </p><p>Source: MHRA sentinel database for adverse reactions</p><p> </p><p>Notes:</p><p> </p><p>The total number of reports received by vaccine brand is not equal to the totals in the table above as some reports included more than one HPV vaccine brand.</p><p> </p><p>The MHRA has received a total of 3,159 serious suspected adverse reaction reports associated with HPV vaccine (data run date 1 November 2017).</p><p> </p><p>All serious reports received via the Yellow Card Scheme are reviewed based on the details received from the reporter. Follow up letters may be sent for missing information such as vaccine brand name, batch number, medical history, results of investigations, diagnoses and details of outcome.</p><p> </p><p>The Commission on Human Medicines has thoroughly reviewed the safety of HPV vaccines and concluded that the evidence does not support a link between HPV vaccination and the development of chronic illnesses.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110248 question first answered 07/11/2017 11:31:40 answering member 4067 label Biography information for Steve Brine
tabling member	4663 label Biography information for Ben Bradley

642297

registered interest
date	22/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when the Joint Committee on Vaccination and Immunisation is expected to make a recommendation on the issuing of HPV vaccination for adolescent boys.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	54217
answer	answer is ministerial correction date of answer 30/11/2016 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), advises Ministers on immunisation related issues, is currently in the process of considering the impact and cost-effectiveness of extending the human papillomavirus (HPV) vaccination to adolescent boys.</p><p> </p><p>The JCVI will need to consider mathematical modelling by Public Health England (PHE) on the impact and cost effectiveness of extending the HPV vaccination to adolescent boys, ahead of developing its advice. PHE is expected to report its modelling assessment to the Committee in early 2017.</p><p> </p><p>The JCVI will consider the analysis from PHE at the earliest opportunity. Once the Committee is satisfied it has reviewed all the necessary evidence it will then be expected to make its advice.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 30/11/2016 17:59:22 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3930 label Biography information for Caroline Lucas

642302

registered interest
date	22/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to conduct an equality impact assessment of HPV vaccination for boys; and whether any such assessment will take place before or after a recommendation from the Joint Committee on Vaccination and Immunisation.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	54216
answer	answer is ministerial correction date of answer 30/11/2016 answer text <p>The Secretary of State for Health is under the public sector equality duty (PSED) including in relation to policies such as new vaccination programmes. Complying with the PSED requires that there is consideration of equality issues during the decision making process and implementation. The consideration of such equality issues will take place as part of the policy making process concerning human papillomavirus (HPV) vaccination for boys.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 54209 question first answered 30/11/2016 17:59:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3930 label Biography information for Caroline Lucas

642305

registered interest
date	22/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he has requested legal advice on whether HPV vaccination for boys is required under the terms of equality legislation; and if he will make a statement.
tabling member constituency	Brighton, Pavilion
tabling member printed	Caroline Lucas
uin	54209
answer	answer is ministerial correction date of answer 30/11/2016 answer text <p>The Secretary of State for Health is under the public sector equality duty (PSED) including in relation to policies such as new vaccination programmes. Complying with the PSED requires that there is consideration of equality issues during the decision making process and implementation. The consideration of such equality issues will take place as part of the policy making process concerning human papillomavirus (HPV) vaccination for boys.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 54216 question first answered 30/11/2016 17:59:09 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3930 label Biography information for Caroline Lucas

522153

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he made of the utility of data from the clinic in Brent and Harrow which has been providing men who have sex with men with HPV vaccinations since 2012 when determining that it was necessary to conduct an HPV vaccination pilot before deciding on a national roll-out; and if he will make a statement.
tabling member constituency	Hazel Grove
tabling member printed	William Wragg
uin	38847
answer	answer is ministerial correction date of answer 10/06/2016 answer text <p>Experience from the two Brent and Harrow clinics providing human papillomavirus vaccinations to men who have sex with men was shared with Public Health England and has helped to inform the development of the pilot. North West London is unlikely to be representative of England as a whole and the pilot will therefore let us consider provision of this vaccination programme in different geographical areas. It will also consider a wider age range than the service provided in these two clinics. The pilot will cover men up to 45 years of age in line with advice from the Joint Committee on Vaccination and Immunisation (JCVI). The pilot will help resolve a range of implementation issues and determine whether a national programme can be delivered through Genito-Urinary Medicine and HIV clinics at a cost effective price in line with the JCVI’s advice.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2016 10:59:07 answering member 3918 label Biography information for Jane Ellison
tabling member	4429 label Biography information for Mr William Wragg

521270

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether he plans for the HPV vaccination programme at sexual health clinics for men who have sex with men to be rolled out nationally at the earliest opportunity or to be implemented through initial pilot projects.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38132
answer	answer is ministerial correction date of answer 02/06/2016 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the expert body that advises the Government on all immunisation matters, advised that a targeted human papillomavirus (HPV) vaccination programme should be undertaken for men who have sex with men (MSM) up to 45 years of age who attend genitourinary medicine and HIV clinics. They noted that this should be subject to procurement of the vaccine and delivery of the programme at a cost-effective price. JCVI acknowledged that finding a way to implement its advice would be challenging and made clear that work was needed by the Department and others to consider commissioning and delivery routes for this programme.</p><p>The Department announced on 26 May 2016 that an HPV vaccination pilot for MSM would start in June.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 38133 question first answered 02/06/2016 15:24:39 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

514076

registered interest
date	19/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department's policies of the 2016 paper by Mesher and others, Reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	34696
answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department’s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department’s policies.</p><p>The answer of 23 March 2016 stated, ‘data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.’ This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.</p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 34693 34694 34695 question first answered 25/04/2016 14:55:51 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw

475722

registered interest
date	15/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the decision making criteria is for the award of the contract for the supply of human papilloma virus vaccine.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	31114
answer	answer is ministerial correction date of answer 23/03/2016 answer text <p>The Department and Public Health England are currently undertaking a procurement exercise to secure vaccine to support the human papillomavirus vaccination programme for girls. As this is a competitive tender, it would not be appropriate to discuss the outcome of the procurement until a contract has been concluded with the successful bidder following the mandatory standstill period.</p><p>The procurement will take account of the costs and benefits of all vaccines offered to establish which provides best value for money for the National Health Service. The award criteria are published on the government’s Contracts Finder website:</p><p>https://www.contractsfinder.service.gov.uk/Notice/813bc859-8662-4c79-822b-f03cc84b8ceb</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 31112 31115 question first answered 23/03/2016 15:25:52 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw

475732

registered interest
date	15/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made on the likely incidence of recurrent respiratory papillomatosis in the event that the (a) quadrivalent vaccine is maintained for UK HPV vaccination programme for girls and (b) bivalent vaccine is introduced for the UK HPV vaccination programme for girls.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	31120
answer	answer is ministerial correction date of answer 23/03/2016 answer text <p>The Department has not estimated the impact on the incidence of recurrent respiratory papillomatosis if the bivalent vaccine replaces the quadrivalent vaccine in the human papillomavirus (HPV) vaccination programme for girls.</p><p>Warwick University is carrying out some limited analysis, in the context of its modelling work on the impact and cost effectiveness of extending HPV vaccination to boys, but the results are academically and commercially confidential, and subject to review by the Joint Committee on Vaccination and Immunisation, the independent expert body that advises Ministers on immunisation matters.</p><p>Estimates of the potential impact of the HPV vaccination programme on cancer and warts, including the incidence of recurrent respiratory papillomatosis, have been previously published by Public Health England in the British Medical Journal in 2011:</p><p>http://www.bmj.com/content/343/bmj.d5775</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 23/03/2016 15:23:53 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw

451411

registered interest
date	03/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what progress his Department is making on rolling out HPV vaccinations to men who have sex with men.
tabling member constituency	Finchley and Golders Green
tabling member printed	Mike Freer
uin	903556
answer	answer is ministerial correction date of answer 09/02/2016 answer text <p>In November 2015, the Joint Committee on Vaccination and Immunisation (JCVI), the expert body that advises the Government on all immunisation matters, advised that a targeted human papillomavirus vaccination programme should be undertaken for men who have sex with men up to 45 years of age who attend genitourinary medicine and HIV clinics. They noted that this should be subject to procurement of the vaccine and delivery of the programme at a cost-effective price.</p><p>JCVI acknowledged that finding a way to implement its advice would be challenging and made clear that work was needed by DH and others to consider commissioning and delivery routes for this programme. This work is already underway and we will announce our plans as soon as we can.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 09/02/2016 15:04:57 answering member 3918 label Biography information for Jane Ellison
tabling member	4004 label Biography information for Mike Freer